Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Canbridge Pharmaceuticals's share price is €0.172.
Canbridge Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.01. Hence, Canbridge Pharmaceuticals's PS Ratio for today is 13.23.
The historical rank and industry rank for Canbridge Pharmaceuticals's PS Ratio or its related term are showing as below:
FRA:MF1'
s PS Ratio Range Over the Past 10 Years
Min: 0.48 Med: 7.46 Max: 265.59
Current: 16.94
During the past 7 years, Canbridge Pharmaceuticals's highest PS Ratio was 265.59. The lowest was 0.48. And the median was 7.46.
FRA:MF1's PS Ratio is ranked worse than 63.33% of 930
companies
in the Biotechnology industry
Industry Median: 9
vs FRA:MF1: 16.94
During the past 7 years, Canbridge Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 273.30% per year. The lowest was -19.20% per year. And the median was 41.00% per year.
Back to Basics: PS Ratio
Canbridge Pharmaceuticals (FRA:MF1) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Canbridge Pharmaceuticals PS Ratio Related Terms
Canbridge Pharmaceuticals PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Canbridge Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canbridge Pharmaceuticals PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where Canbridge Pharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Canbridge Pharmaceuticals's Share Price of today is €0.172.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Canbridge Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Canbridge Pharmaceuticals (FRA:MF1) has a PS Ratio of 13.23 as of Jul. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Canbridge Pharmaceuticals and its competitors. This is 77% above median its historical median of 7.46. Over the past decade, Canbridge Pharmaceuticals' PS Ratio has ranged from 0.48 to 265.59. According to the industry distribution chart, Canbridge Pharmaceuticals ranks #589 out of 930 companies in the Biotechnology industry, placing it in the top 63.3%.
Is Canbridge Pharmaceuticals' PS Ratio too high?
Canbridge Pharmaceuticals' current PS Ratio of 13.23 is 77% above median its 10-year median of 7.46. Over the past 10 years, this metric has ranged from a low of 0.48 to a high of 265.59. The Biotechnology industry median PS Ratio is 9.00. Canbridge Pharmaceuticals' value of 13.23 is 47% above this industry median. Based on the distribution chart, Canbridge Pharmaceuticals ranks #589 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Canbridge Pharmaceuticals has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Canbridge Pharmaceuticals' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Canbridge Pharmaceuticals ranks #589 out of 930 companies for PS Ratio. This places Canbridge Pharmaceuticals in the lower half of its industry. The industry median PS Ratio is 9.00. Canbridge Pharmaceuticals' value of 13.23 is 47% above this benchmark. Historically, Canbridge Pharmaceuticals' own PS Ratio has ranged from 0.48 to 265.59 over the past decade. While the company's 10-year median is 7.46 vs. the industry median of 9.00, Canbridge Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.00, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Canbridge Pharmaceuticals's current PS Ratio of 13.23 is 47% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Canbridge Pharmaceuticals and its competitors. For the Biotechnology industry, the median PS Ratio is 9.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Canbridge Pharmaceuticals's current PS Ratio is 13.23, which is 77% above median its own 10-year median of 7.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canbridge Pharmaceuticals stock overvalued right now?
Canbridge Pharmaceuticals (FRA:MF1) has a current PS Ratio of 13.23. The stock's GF Value™ is €0.03, compared to a current price of €0.17 — trading 473.3% above its estimated fair value. The current PS Ratio is 13.23, which is 77% above median its 10-year median of 7.46 and 47% above the Biotechnology industry median of 9.00. Canbridge Pharmaceuticals' overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Canbridge Pharmaceuticals (FRA:MF1), the current PS Ratio is 13.23 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Canbridge Pharmaceuticals (FRA:MF1) Overvalued in 2026?
Based on GuruFocus' analysis, Canbridge Pharmaceuticals stock appears to be overvalued.
The current stock price of €0.17 is trading 473.3% above its estimated GF Value™ of €0.03.
Key valuation signals for FRA:MF1:
PS Ratio: 13.23 (77% above median its 10-year median of 7.46)
GF Value™: €0.03 vs. price of €0.17 (473.3% above fair value)
Industry Position: 47% above the Biotechnology median (#589 of 930)
No single metric tells the full story. See the FRA:MF1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Canbridge Pharmaceuticals Inc is a biotechnology company engaged in the research, development, and commercialization of therapies targeting rare diseases. Its differentiated portfolio of therapeutics includes biologics, small molecules, and gene therapies, targeting prevalent rare disease indications that have unmet needs and market potential. The Group's portfolio is composed of approved products like Hunterase, Livmarli, and Gaurunning, and various assets currently in development like CAN106, CAN107, CAN104, and CAN105, all these targeting diseases such as Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria, hemophilia A, metabolic disorders, rare cholestatic liver diseases, and neuromuscular diseases. The Group's main market is Mainland China.
48GF Score
Get the complete analysis for FRA:MF1
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MF1 has been successfully added to your 
